WASHINGTON — The Trump administration has prepared an order that would impose a 100% tariff on imports of patented medications and their active ingredients, according to a draft obtained by STAT.
The tariffs could be announced as soon as Thursday, according to a person familiar with the matter. Bloomberg, which first reported on some of the order’s details, also indicated that the announcement could come Thursday. However, it remains possible that the timeline or specifics of the plans could change, reflecting the administration’s evolving stance on pharmaceutical trade practices.
This proposed tariff could significantly impact the pharmaceutical supply chain, potentially leading to increased costs for manufacturers and consumers alike. B2B professionals in regulatory, QA/QC, CMC, sourcing, and portfolio management should prepare for potential disruptions and reassess their strategies in light of these developments.
Get started today with Solo access →
